Latest Memorial Sloan–Kettering Cancer Center Stories
A Perspective piece in the New England Journal of Medicine calls for change in the way researchers and pharmaceutical companies collect and report adverse symptom information in clinical trials submitted to the Food and Drug Administration (FDA), and how the FDA represents this information on drug labels.Ethan Basch, MD, outcomes researcher and medical oncologist at Memorial Sloan-Kettering Cancer Center, recommends that fundamental change is necessary in order to improve the process of...
BETHPAGE, N.Y., March 2 /PRNewswire/ -- The Lustgarten Foundation announced today that it has formed a national pancreatic cancer research consortium, a collaborative effort involving six world-renowned medical institutions to advance the most promising research initiatives aimed at finding a cure for pancreatic cancer. Named the Pancreatic Cancer Research Consortium (PCRC), The Lustgarten Foundation will provide an initial $10 million in grants this year for research in the prevention,...
Annual Fundraising Event To Be Held At Roseland Ballroom In New York City On April 18(th) NEW YORK, Jan. 19 /PRNewswire-USNewswire/ -- The T.J. Martell Foundation announced today that it will honor the Grammy-nominated and multi-platinum selling music artists, Jonas Brothers, along with their management at the 11(th) Annual T.J. Martell Foundation Family Day fundraising event. The celebration will be held on Sunday, April 18(th), 2010 at the legendary Roseland Ballroom, located at 239 West...
NEW YORK, Jan. 6 /PRNewswire/ -- On January 31 and February 6, 2010, thousands of indoor cyclists will team up in the ride against cancer at the fourth annual Cycle for Survival fundraiser, benefiting research on rare cancers at Memorial Sloan-Kettering Cancer Center. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/mskcc/41688/ (Logo: http://www.newscom.com/cgi-bin/prnh/20100106/NY33181LOGO ) A total of 400 teams of up to eight...
Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs. A new study by researchers at Memorial Sloan-Kettering Cancer Center shows that circulating tumor cells "“ cancer cells that break away from a primary tumor and disseminate to other areas of the body "“ can also return to and grow in their tumor of origin, a newly discovered process called...
In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information. A new longitudinal study from researchers at Memorial Sloan-Kettering Cancer Center finds that while clinicians' and patients' reporting of treatment side effects are very different from each other, together they provide a...
NEW YORK, Oct. 20 /PRNewswire/ -- The Society of Memorial Sloan-Kettering Cancer Center (MSKCC) announces the launch of PARK AVENUE POTLUCK CELEBRATIONS (ISBN: 978-0-8478-3344-3; $35.00; OCTOBER 2009), the highly anticipated sequel to its best selling cookbook, PARK AVENUE POTLUCK. Created and authored by members of The Society, the cookbook is released nationwide by Rizzoli on October 20, 2009 and offers advice on how to celebrate in style with a compilation of 80 sensational recipes,...
Breast"“conserving surgery offered to the majority of patientsThere is concern that mastectomy is over-utilized in the United States, which raises questions about the role of surgeons and patient preference in treatment selection for breast cancer. New data from an observational study found that breast-conserving surgery was presented and provided in the majority of patients evaluated. Surgeon recommendations, patient decisions, and failure of breast-conserving surgery were all found to be...
MENLO PARK, Calif. and NEW YORK and BIRMINGHAM, Ala., Sept. 28 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research on drugs of this class began in the 1950s at SRI International. A subsequent scientific collaboration among SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute led to clinical trials on related compounds...
MENLO PARK, Calif., NEW YORK and BIRMINGHAM, Ala., Sept. 25 /PRNewswire/ -- The U.S. Food & Drug Administration has announced the approval of pralatrexate for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). Research on drugs of this class began in the 1950s at SRI International. A subsequent scientific collaboration among SRI International, Memorial Sloan-Kettering Cancer Center, and Southern Research Institute led to clinical trials on related compounds...
